Advaxis (ADXS) 10-Q 10 Sep 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jul. 31, 2020	Sep. 02, 2020
Cover [Abstract]
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Jul. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,227,473
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Current Assets:
Cash and cash equivalents	$ 23,846	$ 32,363
Deferred expenses	1,518	2,353
Deferred offering costs	644
Prepaid expenses and other current assets	1,291	1,433
Total current assets	27,299	36,149
Property and equipment (net of accumulated depreciation)	3,667	4,350
Intangible assets (net of accumulated amortization)	3,841	4,575
Operating right-of-use asset (net of accumulated amortization)	5,030
Other assets	182	183
Total assets	40,019	45,257
Current liabilities:
Accounts payable	414	976
Accrued expenses	1,826	3,478
Common stock warrant liability	33	19
Current portion of operating lease liability	926
Other current liabilities	50	48
Total current liabilities	3,249	4,521
Operating lease liability, net of current portion	5,304
Other liabilities		1,205
Total liabilities	8,553	5,726
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at July 31, 2020 and October 31, 2019; Liquidation preference of $0 at July 31, 2020 and October 31, 2019
Common stock - $0.001 par value; 170,000,000 shares authorized, 62,714,946 and 50,201,671 shares issued and outstanding at July 31, 2020 and October 31, 2019, respectively	62	50
Additional paid-in capital	435,682	423,750
Accumulated deficit	(404,278)	(384,269)
Total stockholders' equity	31,466	39,531
Total liabilities and stockholders' equity	$ 40,019	$ 45,257

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	62,714,946	50,201,671
Common stock, shares outstanding	62,714,946	50,201,671

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Income Statement [Abstract]
Revenue		$ 6	$ 253	$ 20,883
Operating expenses:
Research and development expenses	3,458	7,060	12,239	19,735
General and administrative expenses	2,384	3,076	8,063	8,834
Total operating expenses	5,842	10,136	20,302	28,569
Loss from operations	(5,842)	(10,130)	(20,049)	(7,686)
Other income (expense):
Interest income, net	7	95	108	354
Net changes in fair value of derivative liabilities	7	177	(16)	2,572
Loss on shares issued in settlement of warrants				(1,607)
Other expense	(1)		(2)	(7)
Net loss before benefit for income taxes	(5,829)	(9,858)	(19,959)	(6,374)
Income tax expense			50	50
Net loss	$ (5,829)	$ (9,858)	$ (20,009)	$ (6,424)
Net loss per common share, basic and diluted	$ (0.09)	$ (1)	$ (0.35)	$ (0.94)
Weighted average number of common shares outstanding, basic and diluted	61,634,031	9,870,461	57,963,228	6,813,494

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
OPERATING ACTIVITIES
Net loss	$ (20,009)	$ (6,424)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	708	1,565
Employee stock purchase plan expense	1	3
Loss (gain) on change in value of warrants	16	(2,572)
Loss on shares issued in settlement of warrants		1,607
Loss on disposal of property and equipment		290
Abandonment of intangible assets	892	625
Depreciation expense	683	848
Amortization expense of intangible assets	263	290
Amortization of right-of-use asset	553
Change in operating assets and liabilities:
Accounts receivable		1,664
Prepaid expenses and other current assets	977	(54)
Other assets	1
Accounts payable and accrued expenses	(2,251)	(6,245)
Deferred revenue	50	(18,665)
Operating lease liabilities	(606)
Other liabilities		39
Net cash used in operating activities	(18,722)	(27,029)
INVESTING ACTIVITIES
Purchase of property and equipment		(54)
Proceeds from disposal of property and equipment		8
Cost of intangible assets	(421)	(845)
Net cash used in investing activities	(421)	(891)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	10,621	24,471
Warrant exercise		68
Proceeds from employee stock purchase plan	5	19
Employee tax withholdings paid on equity awards	(2)	(15)
Tax shares sold to pay for employee tax withholdings on equity awards	2	14
Net cash provided by financing activities	10,626	24,557
Net decrease in cash and cash equivalents	(8,517)	(3,363)
Cash and cash equivalents at beginning of period	32,363	45,118
Cash and cash equivalents at end of period	23,846	41,755
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes	50	50
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Shares issued in settlement of warrants		5,462
Warrant liability reclassified into equity	2	53
Pre-funded warrant exercises		1
Commitment fee shares issued for equity line	644
Amounts accrued for offering costs	$ 37

Nature of Operations

Nature of Operations	9 Months Ended
	Jul. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. NATURE OF OPERATIONS Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes Lm Lm Lm Lm TM ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants; ● Attacking the tumor by generating a strong, cancer-specific T cell response; and ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells. Advaxis’ proprietary Lm Lm Going Concern and Management’s Plans The Company has not yet commercialized any human products and the products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern within one year after the date the financial statements are issued. Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, debt financings, clinical collaborations, option and warrant exercises, NOL tax sales, income earned on investments and grants and interest income. From October 2013 through July 31, 2020, the Company raised approximately $305.8 million in gross proceeds ($13.6 million in fiscal year 2020) from various public and private offerings of its common stock. As of July 31, 2020, the Company had approximately $23.8 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least July 2021, the actual amount of cash that it will need to operate is subject to many factors. Over the past several months, the Company has taken steps to obtain additional financing, including the at-the-market (“ATM”) program and the equity line with Lincoln Park Capital. Due to the current state of the Company’s stock price and general market conditions, these programs have not been utilized to the fullest extent, thereby resulting in lower capital availability than anticipated. Management’s plans to mitigate an expected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategic or financing investors. The Company has reduced its operating expenses to $20.3 million for the nine months ended July 31, 2020 as compared to $28.6 million during the comparable prior period. The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	9 Months Ended
	Jul. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of July 31, 2020 has been derived from the Company’s October 31, 2019 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2019 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on December 20, 2019, as amended by Amendment No. 1 thereto on Form 10-K/A filed on January 21, 2020 and by Amendment No. 2 thereto on Form 10-K/A filed on February 28, 2020. Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share (as of July 31, 2020, 327,338 warrants are included in the basic earnings per share computation because the exercise price is $0, and as of July 31, 2019, 13,079,000 pre-funded warrants are included in the basic earnings per share computation because the exercise price is nominal): As of July 31, 2020 2019 Warrants 5,070,888 18,301,804 Stock options 914,577 405,372 Restricted stock units 5,818 16,204 Total 5,991,283 18,723,380 Leases Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases. At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Recent Accounting Standards Recently Adopted Accounting Standards On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. As of the November 1, 2019 effective date, the Company had identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations or condensed statements of cash flows. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment

Property and Equipment	9 Months Ended
	Jul. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	3. PROPERTY AND EQUIPMENT Property and equipment, net consists of the following (in thousands): July 31, 2020 October 31, 2019 Leasehold improvements $ 2,335 $ 2,335 Laboratory equipment 3,405 3,405 Furniture and fixtures 744 744 Computer equipment 409 409 Construction in progress 83 83 Total property and equipment 6,976 6,976 Accumulated depreciation and amortization (3,309 ) (2,626 ) Net property and equipment $ 3,667 $ 4,350 Depreciation expense for the three months ended July 31, 2020 and 2019 was $0.2 million and $0.3 million, respectively. Depreciation expense for the nine months ended July 31, 2020 and 2019 was $0.7 million and $0.8 million, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Jul. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. INTANGIBLE ASSETS Intangible assets, net consist of the following (in thousands): July 31, 2020 October 31, 2019 Patents $ 5,208 $ 5,833 Licenses 777 777 Software 117 117 Total intangibles 6,102 6,727 Accumulated amortization (2,261 ) (2,152 ) Intangible assets $ 3,841 $ 4,575 The expirations of the existing patents range from 2020 to 2040 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $0.3 million were abandoned and were charged to research and development expenses in the statement of operations for each of the three months ended July 31, 2020 and 2019, respectively. Patent applications having a net book value of $0.9 million and $0.6 million were abandoned and were charged to research and development expenses in the statement of operations for the nine months ended July 31, 2020 and 2019, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.1 million for each of the three months ended July 31, 2020 and 2019, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.3 million for each of the nine months ended July 31, 2020 and 2019, respectively. Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets. At July 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal year ending October 31, 2020 (Remaining) $ 79 2021 309 2022 309 2023 309 2024 309 Thereafter 2,526 Total $ 3,841

Accrued Expenses

Accrued Expenses	9 Months Ended
	Jul. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	5. ACCRUED EXPENSES: July 31, 2020 October 31, 2019 Salaries and other compensation $ 743 $ 158 Vendors 604 3,194 Professional fees 479 126 Total accrued expenses $ 1,826 $ 3,478

Common Stock Purchase Warrants

Common Stock Purchase Warrants and Warrant Liability	9 Months Ended
	Jul. 31, 2020
Common Stock Purchase Warrants And Warrant Liability
Common Stock Purchase Warrants and Warrant Liability	6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Warrants As of July 31, 2020, there were outstanding warrants to purchase 5,398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Type of Financing $ - 327,338 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other warrants $ 0.372 70,863 September 2024 September 2018 Public Offering $ 1.25 5,000,000 July 2025 January 2020 Public Offering Grand Total 5,398,226 As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Type of Financing $ - 359,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 72,279 September 2024 September 2018 Public Offering Grand Total 432,142 A summary of warrant activity was as follows (in thousands, except share and per share data): Shares Weighted Weighted Aggregate Outstanding and exercisable warrants at October 31, 2019 432,142 $ 0.08 4.76 $ 114,069 Issued 5,000,000 1.25 Exercised * (33,916 ) 0.02 Outstanding and exercisable warrants at July 31, 2020 5,398,226 $ 1.16 4.90 $ 204,596 * Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock. As of July 31, 2020, the Company had 5,327,363 of its total 5,398,226 outstanding warrants classified as equity (equity warrants). At October 31, 2019, the Company had 359,863 of its total 432,142 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the balance sheet. Warrant Liability As of July 31, 2020, the Company had 70,863 of its total 5,398,226 outstanding warrants classified as liabilities (liability warrants). At October 31, 2019, the Company had 72,279 of its total 432,142 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of July 31, 2020, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.372. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. In measuring the warrant liability at July 31, 2020 and October 31, 2019, the Company used the following inputs in its Monte Carlo simulation model: July 31, 2020 October 31, 2019 Exercise Price $ 0.372 $ 0.372 Stock Price $ 0.58 $ 0.32 Expected Term 4.12 years 4.87 years Volatility % 104.47 % 100.99 % Risk Free Rate 0.16 % 1.51 %

Share Based Compensation

Share Based Compensation	9 Months Ended
	Jul. 31, 2020
Share-based Payment Arrangement [Abstract]
Share Based Compensation	7. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the condensed statement of operations (in thousands): Three Months Ended July 31, Nine Months Ended July 31, 2020 2019 2020 2019 Research and development $ 79 $ 241 $ 233 $ 822 General and administrative 176 223 475 743 Total $ 255 $ 464 $ 708 $ 1,565 Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the nine months ended July 31, 2020 is as follows: Number of Weighted-Average Balance at October 31, 2019 14,706 $ 47.62 Vested (8,608 ) 59.61 Cancelled (280 ) 98.80 Balance at July 31, 2020 5,818 $ 27.40 As of July 31, 2020, there was approximately $0.1 million of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 0.72 years. As of July 31, 2020, the aggregate intrinsic value of non-vested RSU’s was approximately $3,000. Employee Stock Awards Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 0 shares and 408 shares during the three months ended July 31, 2020 and 2019, respectively. Total stock compensation expense associated with employee awards for the three months ended July 31, 2020 and 2019 was approximately $40,000 and $0.2 million, respectively Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 8,608 shares and 10,947 shares during the nine months ended July 31, 2020 and 2019, respectively. Total stock compensation expense associated with employee awards for the nine months ended July 31, 2020 and 2019 was approximately $0.1 million and $0.7 million, respectively. Stock Options A summary of changes in the stock option plan for the nine months ended July 31, 2020 is as follows: Number of Weighted-Average Outstanding at October 31, 2019: 560,490 $ 71.56 Granted 450,000 0.66 Canceled or expired (95,913 ) 58.21 Outstanding at July 31, 2020 914,577 38.08 Vested and Exercisable at July 31, 2020 266,380 $ 125.14 During the nine months end July 31, 2020, the Company granted options to purchase 385,000 and 65,000 shares of its common stock to employees and directors, respectively. The stock options have a ten-year term, vest over three years, and have an exercise price of $0.66. Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended July 31, 2020 and 2019 was approximately $0.2 million and $0.3 million, respectively. For the nine months ended July 31, 2020 and 2019, compensation cost related to the Company’s outstanding stock options was approximately $0.6 million and $0.9 million, respectively. As of July 31, 2020, there was approximately $0.8 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.37 years. As of July 31, 2020, the aggregate intrinsic value of vested and exercisable options was $0 and the aggregate intrinsic value of non-vested options was approximately $42,000. In determining the fair value of the stock options granted during the nine months ended July 31, 2020, the Company used the following inputs in its Black Scholes Merton model: Nine Months Ended Expected Term 5.50-6.50 years Expected Volatility 100.27-105.21 % Expected Dividends 0 % Risk Free Interest Rate 0.36-0.52 % Employee Stock Purchase Plan During the nine months ended July 31, 2020 and 2019, the Company issued 11,148 and 4,585 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	9 Months Ended
	Jul. 31, 2020
Business Combinations [Abstract]
Collaboration and Licensing Agreements	8. COLLABORATION AND LICENSING AGREEMENTS OS Therapies LLC On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agrees to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieves its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis will initiate the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology. Provided that OST meets its ongoing obligation to make its Monthly Payments to Advaxis for six consecutive months, Advaxis agrees to transfer, and OST agrees to take full ownership of, the IND application for ADXS31-164 in its entirety to OST, along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development. Until OST makes its Monthly Payments to Advaxis for six consecutive months, Advaxis will continue to bear the costs of the regulatory filing services related to the IND application for ADXS31-164. Within five business days of achieving the funding milestone of $2,337,500 for the performance of the Children’s Oncology Group study (knowns as the “License Commencement Date”), OST will make a non-refundable and non-creditable payment to Advaxis of $1,550,000 less the cumulative Monthly Payments previously made (the “License Commencement Payment”). Within five days following the License Commencement Date, Advaxis will provide existing drug supply “as is” to OST, and until the drug supply is supplied to OST, Advaxis will bear the storage costs for the drug product. Pursuant to the agreement, the Company is also to receive sales-based milestone payments and royalties on future product sales. In addition, the Company and OST will establish a Joint Steering Committee to oversee the R&D activities. The promises to (1) Maintain the HER2 product until transfer to OST, (2) Provide the IND application ownership for ADX321-164 to OST, (3) Participate in the Joint Steering Committee, (4) Transfer of IP & licensing rights of ADXS31-164 and related Patents, and (5) Provide Clinical Drug Supply represent one combined performance obligation for revenue recognition purposes. The Company concluded that the transfer of the IP and licensing rights provides OST with a functional, or “right to use,” license, and thus the Company will recognize the upfront fees of $1,550,000 from the license at a point in time. The revenue from the transfer of the license cannot be recognized until the transfer of the corresponding IP to OST has occurred and OST has the ability to benefit from the right to use the license. As the right to use the license begins when OST makes the upfront payment within five days of the License Commencement Date and the IP transfers to OST at that time, the upfront fees from the license will be recognized upon the transfer of the intellectual property to OST. Since OST is making $25,000 monthly payments that will be creditable against the $1,550,000, the Company will receive payments prior to the performance of the single distinct performance obligation. Due to this, the Company will defer any of the monthly payments until the IP and licensing rights are transferred to OST. However, if OST terminates the contract, which they are able to do with 60-day notice, the Company would recognize any of the $25,000 monthly payments received when the contract terminates. As of July 31, 2020, OST has made payments totaling $50,000 and this has been recorded as other liabilities in the condensed balance sheet. Elanco Animal Health (formerly Aratana Therapeutics) During the fiscal year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. During the three months ended July 31, 2020 and 2019, Advaxis recognized royalty revenue totaling $0 and $6,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. During the nine months ended July 31, 2020 and 2019, Advaxis recognized royalty revenue totaling approximately $3,000 and $8,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. On July 16, 2019, Aratana announced their shareholders approved a merger agreement with Elanco Animal Health (“Elanco”) whereby Elanco will be the majority shareholder of Aratana. All of the terms of the Aratana Agreement remain in effect. Global BioPharma Inc. On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the nine months ended July 31, 2020 and 2019, the Company recorded $0.3 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jul. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES Legal Proceedings Stendhal On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest. From October 21-23, 2019, an evidentiary hearing for the arbitration was conducted. On April 1, 2020, the Arbitrator issued a final award denying Stendhal’s claim in full. The Arbitrator found that the Company had not repudiated the Agreement and did not owe Stendhal damages, fees, or interest associated with the arbitration. The Arbitrator also denied the Company’s claim that Stendhal breached its obligations to the Company. The parties were ordered to bear their own attorneys’ fees and evenly split administrative fees and expenses for the arbitration.

Leases

Leases	9 Months Ended
	Jul. 31, 2020
Leases [Abstract]
Leases	10. LEASES Operating Leases The Company leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expires in November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided a security deposit of approximately $182,000, which is recorded as Other Assets in the condensed balance sheet. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease. ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. ● Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise. ● Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability. Supplemental balance sheet information related to leases as of July 31, 2020 was as follows (in thousands): Operating Leases:  Operating lease right-of-use assets $ 5,030 Operating lease liability $ 926 Operating lease liability, net of current portion 5,304 Total operating lease liabilities $ 6,230 Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three For the Nine Months Ended Operating lease cost General and administrative 290 869 Short-term lease cost General and administrative 83 249 Variable lease cost General and administrative $ 108 $ 282 Total lease expense $ 481 $ 1,400 Other information related to leases where the Company is the lessee is as follows: For the Nine Weighted-average remaining lease term 5.3 years Weighted-average discount rate 6.5 % Supplemental cash flow information related to operating leases was as follows: For the Three For the Nine Cash paid for operating lease liabilities $ 311 $ 922 Future minimum lease payments under non-cancellable leases as of July 31, 2020 were as follows: Fiscal Year ending October 31, 2020 (Remaining) $ 311 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total minimum lease payments 7,376 Less: Imputed interest (1,146 ) Total $ 6,230 Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands): Fiscal Year ending October 31, 2020 $ 1,233 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total $ 8,298 Under ASC 840, rent expense for each of the years ended October 31, 2019 and 2018 was approximately $1.2 million.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Jul. 31, 2020
Equity [Abstract]
Stockholders' Equity	11. STOCKHOLDERS’ EQUITY A summary of the changes in stockholders’ equity for the three and nine months ended July 31, 2020 and 2019 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2018 - $ - 4,634,189 $ 5 $ 391,703 $ (367,657 ) $ 24,051 Stock based compensation - - 9,811 - 622 - 622 Tax withholdings paid on equity awards - - - - (11 ) - (11 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 11 - 11 Issuance of shares to employees under ESPP Plan - - 2,007 - 9 - 9 ESPP Expense - - - - 1 1 Net Income - - - - 12,817 12,817 Balance at January 31, 2019 - $ - 4,646,007 $ 5 $ 392,335 $ (354,840 ) $ 37,500 Stock based compensation - - 693 - 479 - 479 Tax withholdings paid on equity awards - - - - (3 ) - (3 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 3 - 3 Issuance of shares to employees under ESPP Plan - - 1,505 - 7 - 7 Warrant exercises - - 15,300 - 68 - 68 Warrant liability reclassified into equity - - - - 53 - 53 ESPP Expense - - - - 1 1 Shares issued in settlement of warrants - - 856,865 1 5,462 - 5,463 Advaxis public offerings, net of offering costs - - 2,500,000 2 8,980 - 8,982 Net Loss - - - - - (9,383 ) (9,383 ) Balance at April 30, 2019 - $ - 8,020,370 $ 8 $ 407,385 $ (364,223 ) $ 43,170 Stock based compensation 408 - 464 - 464 Tax withholdings paid on equity awards - - - - 1 - (1 ) Tax shares sold to pay for tax withholdings on equity awards - - - - (1 ) - 1 Issuance of shares to employees under ESPP Plan - - 1,073 - 3 - 3 Shares issued in settlement of warrants - - 577,000 1 - - 1 Advaxis public offerings, net of offering costs - - 10,650,000 11 15,478 - 15,489 Net Loss - - - - - (9,858 ) (9,858 ) Balance at July 31, 2019 - $ - 19,248,851 $ 20 $ 423,330 $ (374,081 ) $ 49,269 Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock based compensation - - 2,957 - 242 - 242 Advaxis public offerings, net of offering costs - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Income - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 Stock based compensation - - 5,651 - 210 - 210 Warrant exercises - - 7,500 - - - - Issuance of shares to employees under ESPP Plan - - 2,694 - 2 - 2 Net Income - - - - - (6,323 ) (6,323 ) Balance at April 30, 2020 - $ - 60,252,444 $ 60 $ 433,826 $ (398,449 ) $ 35,437 Stock based compensation - - - - 255 - 255 Tax withholdings paid on equity awards - - - - (1 ) - (1 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 1 - 1 Issuance of shares to employees under ESPP Plan - - 2,899 - 2 - 2 At-the-market shares issued, net of offering costs - - 1,375,337 1 956 - 957 Commitment fee shares issued for equity line - - 1,084,266 1 643 - 644 Net Income - - - - - (5,829 ) (5,829 ) Balance at July 31, 2020 - $ - 62,714,946 $ 62 $ 435,682 $ (404,278 ) $ 31,466 On February 21, 2019, the Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) increase the number of authorized shares of common stock from 95,000,000 to 170,000,000 and also voted to approve an amendment to the Certificate of Incorporation allow the Company to execute a reverse stock split of common stock at the discretion of the Board of Directors. The amendment to increase the number of authorized shares of common stock became effective upon filing of the amendment with the Secretary of State of the State of Delaware on February 28, 2019. Additionally, on March 29, 2019, the Company executed a 1 for 15 reverse stock split. In April 2019, the Company issued 2,500,000 shares of the Company’s common stock in a public offering at $4.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $9 million. In July 2019, the Company closed on an underwritten public offering of 10,650,000 shares of its common stock, pre-funded warrants to purchase 13,656,000 shares of common stock and warrants to purchase up to 17,142,000 shares of common stock at a public offering price of $1.20, for gross proceeds of $17.0 million. Each share of common stock or pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001 per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80 per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations. The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuance and (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending 15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than the then-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $15.5 million. In January 2020, the Company closed on a public offering of 10,000,000 shares of its common stock at a public offering price of $1.05, for gross proceeds of $10.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 5,000,000 shares of common stock. The warrants have an exercise price per share of $1.25, are exercisable during the period beginning on the six-month anniversary of the date of its issuance (the “Initial Exercise Date”) and will expire on the fifth anniversary of the Initial Exercise Date. The warrants contain a change of control provision whereby if the change of control is within the Company’s control, the warrants could be settled in cash based on the Black-Scholes value of the warrants at the option of the warrant holder. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $9.6 million. At the Annual Meeting of Stockholders of the Company held on May 4, 2020, the stockholders ratified and approved an amendment to the Company’s 2015 Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such Plan from 877,744 shares to 6,000,000 shares. In May 2020, the Company entered into a sales agreement related to an ATM equity offering program pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners, as sales agent. From May 2020 to July 2020, the Company sold 1,375,337 shares of its common stock under the ATM program for $1.085 million, or an average of $0.79 per share, and received net proceeds of $0.957 million, net of commissions of $35,000. Lincoln Park Purchase Agreement On July 30, 2020, the Company entered into a Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Over the 36-month term of the Purchase Agreement, the Company has the right, but not the obligation, from time to time, to sell to Lincoln Park up to an aggregate amount of $20,000,000 of shares of common stock, in its sole discretion and subject to certain conditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchase up to 1,000,000 shares (the “Regular Purchase Share Limit”) of its Common Stock (each such purchase, a “Regular Purchase”). Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $1,000,000, unless the parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for the Company’s common stock on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for the Company’s common stock during the ten trading days prior to the purchase date. As consideration for entering into the Purchase Agreement, the Company issued 1,084,266 shares of common stock to Lincoln Park as a commitment fee. The shares were valued at approximately $0.6 million and were recorded as deferred offering expenses in the condensed balance sheet. The deferred charges will be charged against paid-in capital upon future proceeds from the sale of common stock under the Lincoln Park Purchase Agreement.

Fair Value

Fair Value	9 Months Ended
	Jul. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value	12. FAIR VALUE The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2020 and October 31, 2019 (in thousands): July 31, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 33 $ 33 October 31, 2019 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 19 $ 19 The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: For the Ended Beginning balance $ 19 Warrant exercises (2 ) Change in fair value 16 Ending Balance $ 33

Subsequent Events

Subsequent Events	9 Months Ended
	Jul. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On August 3, 2020, Lincoln Park purchased 3,510,527 shares of common stock for gross proceeds of approximately $2 million. The net proceeds to the Company from the transaction was approximately $1.9 million. On September 4, 2020, the Company and Molly Henderson, Executive Vice President and Chief Financial Officer, announced that Ms. Henderson is stepping down as Chief Financial Officer effective September 25, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	9 Months Ended
	Jul. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation/Estimates	Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of July 31, 2020 has been derived from the Company’s October 31, 2019 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2019 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on December 20, 2019, as amended by Amendment No. 1 thereto on Form 10-K/A filed on January 21, 2020 and by Amendment No. 2 thereto on Form 10-K/A filed on February 28, 2020.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share (as of July 31, 2020, 327,338 warrants are included in the basic earnings per share computation because the exercise price is $0, and as of July 31, 2019, 13,079,000 pre-funded warrants are included in the basic earnings per share computation because the exercise price is nominal): As of July 31, 2020 2019 Warrants 5,070,888 18,301,804 Stock options 914,577 405,372 Restricted stock units 5,818 16,204 Total 5,991,283 18,723,380
Leases	Leases Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases. At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.
Recent Accounting Standards	Recent Accounting Standards Recently Adopted Accounting Standards On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. As of the November 1, 2019 effective date, the Company had identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations or condensed statements of cash flows. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	9 Months Ended
	Jul. 31, 2020
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share	The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share (as of July 31, 2020, 327,338 warrants are included in the basic earnings per share computation because the exercise price is $0, and as of July 31, 2019, 13,079,000 pre-funded warrants are included in the basic earnings per share computation because the exercise price is nominal): As of July 31, 2020 2019 Warrants 5,070,888 18,301,804 Stock options 914,577 405,372 Restricted stock units 5,818 16,204 Total 5,991,283 18,723,380

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Jul. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following (in thousands): July 31, 2020 October 31, 2019 Leasehold improvements $ 2,335 $ 2,335 Laboratory equipment 3,405 3,405 Furniture and fixtures 744 744 Computer equipment 409 409 Construction in progress 83 83 Total property and equipment 6,976 6,976 Accumulated depreciation and amortization (3,309 ) (2,626 ) Net property and equipment $ 3,667 $ 4,350

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Jul. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets, net consist of the following (in thousands): July 31, 2020 October 31, 2019 Patents $ 5,208 $ 5,833 Licenses 777 777 Software 117 117 Total intangibles 6,102 6,727 Accumulated amortization (2,261 ) (2,152 ) Intangible assets $ 3,841 $ 4,575
Schedule of Carrying Value of Intangible Assets	At July 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal year ending October 31, 2020 (Remaining) $ 79 2021 309 2022 309 2023 309 2024 309 Thereafter 2,526 Total $ 3,841

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Jul. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	July 31, 2020 October 31, 2019 Salaries and other compensation $ 743 $ 158 Vendors 604 3,194 Professional fees 479 126 Total accrued expenses $ 1,826 $ 3,478

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants and Warrant Liability (Tables)	9 Months Ended
	Jul. 31, 2020
Common Stock Purchase Warrants And Warrant Liability
Schedule of Outstanding Warrants	As of July 31, 2020, there were outstanding warrants to purchase 5,398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Type of Financing $ - 327,338 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other warrants $ 0.372 70,863 September 2024 September 2018 Public Offering $ 1.25 5,000,000 July 2025 January 2020 Public Offering Grand Total 5,398,226 As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Type of Financing $ - 359,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 72,279 September 2024 September 2018 Public Offering Grand Total 432,142
Schedule of Warrants Activity	A summary of warrant activity was as follows (in thousands, except share and per share data): Shares Weighted Weighted Aggregate Outstanding and exercisable warrants at October 31, 2019 432,142 $ 0.08 4.76 $ 114,069 Issued 5,000,000 1.25 Exercised * (33,916 ) 0.02 Outstanding and exercisable warrants at July 31, 2020 5,398,226 $ 1.16 4.90 $ 204,596 * Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.
Schedule of Assumptions Used in Warrant Liability	In measuring the warrant liability at July 31, 2020 and October 31, 2019, the Company used the following inputs in its Monte Carlo simulation model: July 31, 2020 October 31, 2019 Exercise Price $ 0.372 $ 0.372 Stock Price $ 0.58 $ 0.32 Expected Term 4.12 years 4.87 years Volatility % 104.47 % 100.99 % Risk Free Rate 0.16 % 1.51 %

Share Based Compensation (Table

Share Based Compensation (Tables)	9 Months Ended
	Jul. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Share Based Compensation Expense	The following table summarizes share-based compensation expense included in the condensed statement of operations (in thousands): Three Months Ended July 31, Nine Months Ended July 31, 2020 2019 2020 2019 Research and development $ 79 $ 241 $ 233 $ 822 General and administrative 176 223 475 743 Total $ 255 $ 464 $ 708 $ 1,565
Summary of RSU Activity and Related Information	A summary of the Company’s RSU activity and related information for the nine months ended July 31, 2020 is as follows: Number of Weighted-Average Balance at October 31, 2019 14,706 $ 47.62 Vested (8,608 ) 59.61 Cancelled (280 ) 98.80 Balance at July 31, 2020 5,818 $ 27.40
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the nine months ended July 31, 2020 is as follows: Number of Weighted-Average Outstanding at October 31, 2019: 560,490 $ 71.56 Granted 450,000 0.66 Canceled or expired (95,913 ) 58.21 Outstanding at July 31, 2020 914,577 38.08 Vested and Exercisable at July 31, 2020 266,380 $ 125.14
Summary of Fair Value of Stock Options Granted of BSM	In determining the fair value of the stock options granted during the nine months ended July 31, 2020, the Company used the following inputs in its Black Scholes Merton model: Nine Months Ended Expected Term 5.50-6.50 years Expected Volatility 100.27-105.21 % Expected Dividends 0 % Risk Free Interest Rate 0.36-0.52 %

Leases (Tables)

Leases (Tables)	9 Months Ended
	Jul. 31, 2020
Leases [Abstract]
Schedule of Supplemental Balance Sheet Related to Leases	Supplemental balance sheet information related to leases as of July 31, 2020 was as follows (in thousands): Operating Leases:  Operating lease right-of-use assets $ 5,030 Operating lease liability $ 926 Operating lease liability, net of current portion 5,304 Total operating lease liabilities $ 6,230
Schedule of Lease Expenses	Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three For the Nine Months Ended Operating lease cost General and administrative 290 869 Short-term lease cost General and administrative 83 249 Variable lease cost General and administrative $ 108 $ 282 Total lease expense $ 481 $ 1,400
Schedule of Other Information Related to Leases	Other information related to leases where the Company is the lessee is as follows: For the Nine Weighted-average remaining lease term 5.3 years Weighted-average discount rate 6.5 %
Schedule of Cash Flow Information Related to Leases	Supplemental cash flow information related to operating leases was as follows: For the Three For the Nine Cash paid for operating lease liabilities $ 311 $ 922
Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases	Future minimum lease payments under non-cancellable leases as of July 31, 2020 were as follows: Fiscal Year ending October 31, 2020 (Remaining) $ 311 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total minimum lease payments 7,376 Less: Imputed interest (1,146 ) Total $ 6,230
Schedule of Future Minimum Payments Under Operating Lease	Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands): Fiscal Year ending October 31, 2020 $ 1,233 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total $ 8,298

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Jul. 31, 2020
Equity [Abstract]
Summary of Stockholders Equity	A summary of the changes in stockholders’ equity for the three and nine months ended July 31, 2020 and 2019 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2018 - $ - 4,634,189 $ 5 $ 391,703 $ (367,657 ) $ 24,051 Stock based compensation - - 9,811 - 622 - 622 Tax withholdings paid on equity awards - - - - (11 ) - (11 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 11 - 11 Issuance of shares to employees under ESPP Plan - - 2,007 - 9 - 9 ESPP Expense - - - - 1 1 Net Income - - - - 12,817 12,817 Balance at January 31, 2019 - $ - 4,646,007 $ 5 $ 392,335 $ (354,840 ) $ 37,500 Stock based compensation - - 693 - 479 - 479 Tax withholdings paid on equity awards - - - - (3 ) - (3 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 3 - 3 Issuance of shares to employees under ESPP Plan - - 1,505 - 7 - 7 Warrant exercises - - 15,300 - 68 - 68 Warrant liability reclassified into equity - - - - 53 - 53 ESPP Expense - - - - 1 1 Shares issued in settlement of warrants - - 856,865 1 5,462 - 5,463 Advaxis public offerings, net of offering costs - - 2,500,000 2 8,980 - 8,982 Net Loss - - - - - (9,383 ) (9,383 ) Balance at April 30, 2019 - $ - 8,020,370 $ 8 $ 407,385 $ (364,223 ) $ 43,170 Stock based compensation 408 - 464 - 464 Tax withholdings paid on equity awards - - - - 1 - (1 ) Tax shares sold to pay for tax withholdings on equity awards - - - - (1 ) - 1 Issuance of shares to employees under ESPP Plan - - 1,073 - 3 - 3 Shares issued in settlement of warrants - - 577,000 1 - - 1 Advaxis public offerings, net of offering costs - - 10,650,000 11 15,478 - 15,489 Net Loss - - - - - (9,858 ) (9,858 ) Balance at July 31, 2019 - $ - 19,248,851 $ 20 $ 423,330 $ (374,081 ) $ 49,269 Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock based compensation - - 2,957 - 242 - 242 Advaxis public offerings, net of offering costs - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Income - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 Stock based compensation - - 5,651 - 210 - 210 Warrant exercises - - 7,500 - - - - Issuance of shares to employees under ESPP Plan - - 2,694 - 2 - 2 Net Income - - - - - (6,323 ) (6,323 ) Balance at April 30, 2020 - $ - 60,252,444 $ 60 $ 433,826 $ (398,449 ) $ 35,437 Stock based compensation - - - - 255 - 255 Tax withholdings paid on equity awards - - - - (1 ) - (1 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 1 - 1 Issuance of shares to employees under ESPP Plan - - 2,899 - 2 - 2 At-the-market shares issued, net of offering costs - - 1,375,337 1 956 - 957 Commitment fee shares issued for equity line - - 1,084,266 1 643 - 644 Net Income - - - - - (5,829 ) (5,829 ) Balance at July 31, 2020 - $ - 62,714,946 $ 62 $ 435,682 $ (404,278 ) $ 31,466

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Jul. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2020 and October 31, 2019 (in thousands): July 31, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 33 $ 33 October 31, 2019 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 19 $ 19
Schedule of Changes in Fair Value of Warrant Liabilities	The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: For the Ended Beginning balance $ 19 Warrant exercises (2 ) Change in fair value 16 Ending Balance $ 33

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended		91 Months Ended
	May 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from public offering	$ 40,000	$ 9,600	$ 15,500	$ 1,085		$ 13,600	$ 17,000	$ 305,800
Cash and cash equivalents				23,846		23,846		$ 23,846	$ 32,363
Operating expenses				$ 5,842	$ 10,136	$ 20,302	$ 28,569

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Jul. 31, 2020	Nov. 02, 2019	Oct. 31, 2019	Jul. 31, 2019
Exercise price	$ 0
Pre-funded warrants				$ 13,079,000
Operating lease liability	$ 926
Right to use asset	$ 5,030
ASC 842 [Member]
Operating lease liability		$ 6,800
Right to use asset		5,600
Accrued rent liability, current		900
Lease incentive obligation, current		$ 300
Warrants [Member]
Number of securities included in computation of basic earnings per share	$ 327,338

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Total	5,991,283	18,723,380
Warrants [Member]
Total	5,070,888	18,301,804
Stock Options [Member]
Total	914,577	405,372
Restricted Stock Units [Member]
Total	5,818	16,204

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 200	$ 300	$ 683	$ 848

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,335
Laboratory equipment	3,405	3,405
Furniture and fixtures	744	744
Computer equipment	409	409
Construction in progress	83	83
Total property and equipment	6,976	6,976
Accumulated depreciation and amortization	(3,309)	(2,626)
Net property and equipment	$ 3,667	$ 4,350

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Finite lived patents expirations year			The expirations of the existing patents range from 2020 to 2040
Book value patent applications, net			$ 892	$ 625
Intangible asset amortization expense			263	290
Research and Development [Member]
Book value patent applications, net	$ 300	$ 300	900	600
General and Administrative [Member]
Intangible asset amortization expense	$ 100	$ 100	$ 300	$ 300

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,208	$ 5,833
Licenses	777	777
Software	117	117
Total intangibles	6,102	6,727
Accumulated amortization	(2,261)	(2,152)
Intangible assets	$ 3,841	$ 4,575

Intangible Assets - Schedule of

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Jul. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (Remaining)	$ 79
2021	309
2022	309
2023	309
2024	309
Thereafter	2,526
Total	$ 3,841

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Payables and Accruals [Abstract]
Salaries and other compensation	$ 743	$ 158
Vendors	604	3,194
Professional fees	479	126
Total accrued expenses	$ 1,826	$ 3,478

Common Stock Purchase Warrant_3

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - $ / shares	Jul. 31, 2020	May 31, 2020	Oct. 31, 2019	Jul. 31, 2019
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	5,398,226		432,142
Warrant exercise price per share	$ 0.372	$ 0.79	$ 0.372	$ 1.20
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	5,327,363		359,863
Warrants outstanding	5,398,226		432,142
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	70,863		72,279
Warrants outstanding	5,398,226		432,142
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 0		$ 0
Minimum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.372
Maximum [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock				17,142,000
Warrant exercise price per share	281.25		$ 281.25
Maximum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 22.50

Common Stock Purchase Warrant_4

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2020	Oct. 31, 2019	May 31, 2020	Jul. 31, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372	$ 0.79	$ 1.20
Number of Shares Underlying Warrants	5,398,226	432,142
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price
Number of Shares Underlying Warrants	327,338	359,838
Expiration Date	Jul. 31, 2024	Jul. 31, 2024
Type of Financing	July 2019 Public Offering	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25	$ 281.25
Number of Shares Underlying Warrants	25	25
Type of Financing	Other Warrants	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	70,863	72,279
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Type of Financing	September 2018 Public Offering	September 2018 Public Offering
Exercise Price Range Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.25
Number of Shares Underlying Warrants	5,000,000
Expiration Date	Jul. 31, 2025
Type of Financing	January 2020 Public Offering

Common Stock Purchase Warrant_5

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Jul. 31, 2020USD ($)$ / sharesshares
Common Stock Purchase Warrants And Warrant Liability
Number of Warrants, Outstanding and exercisable warrants, Beginning balance | shares	432,142
Number of Warrants, Issued | shares	5,000,000
Number of Warrants, Exercised | shares	(33,916)	[1]
Number of Warrants, Outstanding and exercisable warrants, Ending balance | shares	5,398,226
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning | $ / shares	$ 0.08
Weighted Average Exercise Price, Issued | $ / shares	1.25
Weighted Average Exercise Price, Exercised | $ / shares	0.02	[1]
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending | $ / shares	$ 1.16
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	4 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	4 years 10 months 25 days
Aggregate Intrinsic Value, Beginning | $	$ 114,069
Aggregate Intrinsic Value, Ending | $	$ 204,596
[1]	Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

Common Stock Purchase Warrant_6

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical)	9 Months Ended
	Jul. 31, 2020shares
Common Stock Purchase Warrants And Warrant Liability
Cashless warrant exercise	32,500
Number of common stock shares issued	32,500

Common Stock Purchase Warrant_7

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details)	Jul. 31, 2020$ / shares	May 31, 2020$ / shares	Oct. 31, 2019$ / shares	Jul. 31, 2019$ / shares
Class of Warrant or Right [Line Items]
Warrants exercise price	$ 0.372	$ 0.79	$ 0.372	$ 1.20
Warrant stock price	0
Warrant Liability [Member] | Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price	0.372		0.372
Warrant Liability [Member] | Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrant stock price	$ 0.58		$ 0.32
Warrant Liability [Member] | Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term	4 years 1 month 13 days		4 years 10 months 14 days
Warrant Liability [Member] | Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	104.47		100.99
Warrant Liability [Member] | Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.16		1.51

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019	Oct. 31, 2019
Unrecognized compensation cost related to non-vested stock option awards	$ 800		$ 800
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 4 months 13 days
Aggregate intrinsic value of non-vested RSU	0		$ 0
Stock compensation expense	$ 255	$ 464	$ 708	$ 1,565
Stock granted options to purchase			450,000
Stock option exercise price	$ 38.08		$ 38.08		$ 71.56
Aggregate intrinsic value of vested and exercisable options	$ 0		$ 0
Aggregate intrinsic value of non-vested options	42		42
Compensation cost related to outstanding stock options	$ 200	$ 300	$ 600	$ 900
Employees [Member]
Stock granted options to purchase			385,000
Directors [Member]
Stock granted options to purchase			65,000
Employees and Directors [Member]
Stock option term			10 years
Stock option vesting period			3 years
Stock option exercise price	$ 0.66		$ 0.66
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan			11,148	4,585
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	$ 100		$ 100
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			8 months 19 days
Aggregate intrinsic value of non-vested RSU	$ 3		$ 3
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	0	408	8,608	10,947
Stock compensation expense	$ 40	$ 200	$ 100	$ 700

Share Based Compensation - Summ

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Share-based compensation expense	$ 255	$ 464	$ 708	$ 1,565
Research and Development [Member]
Share-based compensation expense	79	241	233	822
General and Administrative [Member]
Share-based compensation expense	$ 176	$ 223	$ 475	$ 743

Share Based Compensation - Su_2

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Jul. 31, 2020$ / sharesshares
Number of RSUs, Unvested Beginning Balance | shares	14,706
Number of RSUs, Vested | shares	(8,608)
Number of RSUs, Cancelled | shares	(280)
Number of RSUs, Unvested Ending Balance | shares	5,818
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 47.62
Weighted-Average Grant Date Fair Value, Vested | $ / shares	59.61
Weighted-Average Grant Date Fair Value, Cancelled | $ / shares	98.80
Weighted-Average Grant Date Fair Value, Unvested Ending Balance | $ / shares	$ 27.40

Share Based Compensation - Su_3

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	9 Months Ended
	Jul. 31, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options, Beginning Balance | shares	560,490
Number of Options, Granted | shares	450,000
Number of Options, Cancelled or Expired | shares	(95,913)
Number of Options, Ending Balance | shares	914,577
Number of Options, Vested and Exercisable | shares	266,380
Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares	$ 71.56
Weighted-Average Exercise Price, Granted | $ / shares	0.66
Weighted-Average Exercise Price, Cancelled or Expired | $ / shares	58.21
Weighted-Average Exercise Price, Outstanding, Ending | $ / shares	38.08
Weighted-Average Exercise Price, Vested and Exercisable | $ / shares	$ 125.14

Share Based Compensation - Su_4

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	9 Months Ended
	Jul. 31, 2020
Expected Dividends	0.00%
Minimum [Member]
Expected Term	5 years 6 months
Expected Volatility	100.27%
Risk Free Interest Rate	0.36%
Maximum [Member]
Expected Term	6 years 6 months
Expected Volatility	105.21%
Risk Free Interest Rate	0.52%

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details Narrative) - USD ($)	Sep. 04, 2018	Jul. 31, 2020	Apr. 30, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Revenue				$ 6,000	$ 253,000	$ 20,883,000
OS Therapies [Member]
Deferred revenue		50,000			50,000
OS Therapies [Member] | Within Five Business Days [Member]
Funding milestone payment	$ 2,337,500
Non-refundable and non-creditable payment	1,550,000
Upfront fees, amount	1,550,000
OS Therapies [Member] | Creditable [Member]
Funding milestone payment	25,000
Non-refundable and non-creditable payment	1,550,000
OS Therapies [Member] | Within 60-Day Notice [Member]
Funding milestone payment	$ 25,000
Development, License and Supply Agreement [Member] | OS Therapies [Member]
Revenue			$ 25,000
Funding milestone payment			$ 2,337,500
Aratana Agreement [Member] | Royalty [Member]
Revenue		$ 0		$ 6,000	3,000	8,000
Exclusive Licensing Agreement [Member] | License [Member]
Revenue					$ 300,000	$ 300,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Especificos Stendhal SA de CV [Member] $ in Thousands	Sep. 19, 2018USD ($)
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Jul. 31, 2020	Oct. 31, 2019	Oct. 31, 2018
Leases [Abstract]
Operating lease expiration	Nov. 30, 2025
Security deposit	$ 182
Rent expense		$ 1,200	$ 1,200

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 5,030
Operating lease liability	926
Operating lease liability, net of current portion	5,304
Total operating lease liabilities	$ 6,230

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jul. 31, 2020	Jul. 31, 2020
Operating lease cost	$ 290	$ 869
Short-term lease cost	83	249
Variable lease cost	108	282
Total lease expense	$ 481	$ 1,400

Leases - Schedule of Other Info

Leases - Schedule of Other Information Related to Leases (Details)	Jul. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term	5 years 3 months 19 days
Weighted-average discount rate	6.50%

Leases - Schedule of Cash Flow

Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jul. 31, 2020	Jul. 31, 2020
Leases [Abstract]
Cash paid for operating lease liabilities	$ 311	$ 922

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) $ in Thousands	Jul. 31, 2020USD ($)
Leases [Abstract]
2020 (Remaining)	$ 311
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total minimum lease payments	7,376
Less: Imputed interest	(1,146)
Total	$ 6,230

Leases - Schedule of Future M_2

Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) $ in Thousands	Jul. 31, 2020USD ($)
Leases [Abstract]
2020	$ 1,233
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total	$ 8,298

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jul. 30, 2020	Mar. 29, 2019	May 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	May 04, 2020	Apr. 30, 2020	Oct. 31, 2019	Feb. 21, 2019
Common stock, shares authorized							170,000,000				170,000,000		170,000,000			170,000,000	95,000,000
Reverse stock split, description		1 for 15 reverse stock split.
Proceeds from sale of common shares							$ 1,375,337
Pre-funded warrants to purchase common shares					13,656,000				13,656,000			13,656,000
Number of warrants to purchase common stock							5,398,226				5,398,226		5,398,226			432,142
Warrant exercise price per share			$ 0.79		$ 1.20		$ 0.372		$ 1.20		$ 0.372	$ 1.20	$ 0.372			$ 0.372
Net proceeds from offering			$ 40,000	$ 9,600	$ 15,500		$ 1,085				$ 13,600	$ 17,000	$ 305,800
Warrant description												Each share of common stock or pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001 per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80 per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations. The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuance and (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending 15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than the then-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $15.5 million.
Number of common stock shares											32,500
Number of common stock values								$ 9,628	$ 15,489	$ 8,982
Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common stock, shares authorized	20,000,000
Share price per share	$ 0.10
Net proceeds from offering	$ 1,000
Number of common stock shares	1,084,266
Number of common stock values	$ 600
Agreement description	Over the 36-month term of the Purchase Agreement, the Company has the right, but not the obligation, from time to time, to sell to Lincoln Park up to an aggregate amount of $20,000,000 of shares of common stock, in its sole discretion and subject to certain conditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchase up to 1,000,000 shares (the "Regular Purchase Share Limit") of its Common Stock (each such purchase, a "Regular Purchase"). Lincoln Park's maximum obligation under any single Regular Purchase will not exceed $1,000,000, unless the parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for the Company's common stock on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for the Company's common stock during the ten trading days prior to the purchase date.
Pre-funded Warrants [Member]
Number of warrants to purchase common stock					1				1			1
Warrant exercise price per share					$ 0.75				$ 0.75			$ 0.75
ATM Program [Member]
Net proceeds from offering			957
Proceeds from commission			$ 35
Maximum [Member]
Number of warrants to purchase common stock					17,142,000				17,142,000			17,142,000
Warrant exercise price per share							$ 281.25				$ 281.25		$ 281.25			281.25
Maximum [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Number of warrants to purchase common stock	1,000,000
Maximum [Member] | 2015 Incentive Plan [Member]
Common stock, shares authorized														6,000,000
Minimum [Member]
Warrant exercise price per share							$ 0				$ 0		$ 0			$ 0
Minimum [Member] | 2015 Incentive Plan [Member]
Common stock, shares authorized														877,744
Public Offering [Member]
Number of common stock shares sold				10,000,000		2,500,000
Share price per share						$ 4				$ 4					$ 1.05
Proceeds from sale of common shares				$ 10,500		$ 9,000
Pre-funded warrants to purchase common shares					10,650,000				10,650,000			10,650,000
Private Placement [Member]
Number of warrants to purchase common stock															5,000,000
Warrant exercise price per share															$ 1.25

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Jul. 31, 2020	Apr. 30, 2020	Jan. 31, 2020	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Beginning balance	$ 35,437	$ 41,548	$ 39,531	$ 43,170	$ 37,500	$ 24,051	$ 39,531	$ 24,051
Stock based compensation	255	210	242	464	479	622
Tax withholdings paid on equity awards	(1)			(1)	(3)	(11)
Tax shares sold to pay for tax withholdings on equity awards	1			1	3	11
Issuance of shares to employees under ESPP Plan	2	2	2	3	7	9
ESPP Expense					1	1
Advaxis public offerings, net of offering costs			9,628	15,489	8,982
Advaxis public offerings, net of offering costs, shares							32,500
Warrant exercises			2		68
Warrant liability reclassified into equity					53		$ 2	53
Shares issued in settlement of warrants				1	5,463
At-the-market shares issued	957
Commitment fee shares issued for equity line	644						644
Net Income	(5,829)	(6,323)	(7,857)	(9,858)	(9,383)	12,817	(20,009)	(6,424)
Ending balance	31,466	35,437	41,548	49,269	43,170	37,500	31,466	49,269
Preferred Stock [Member]
Beginning balance
Beginning balance, shares
Stock based compensation
Stock based compensation, shares
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
ESPP Expense
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Warrant exercises, shares
Warrant liability reclassified into equity
Shares issued in settlement of warrants
Shares issued in settlement of warrants, shares
At-the-market shares issued
At-the-market shares issued, shares
Commitment fee shares issued for equity line
Commitment fee shares issued for equity line, shares
Net Income
Ending balance
Ending balance, shares
Common Stock [Member]
Beginning balance	$ 60	$ 60	$ 50	$ 8	$ 5	$ 5	$ 50	$ 5
Beginning balance, shares	60,252,444	60,236,599	50,201,671	8,020,370	4,646,007	4,634,189	50,201,671	4,634,189
Stock based compensation
Stock based compensation, shares		5,651	2,957	408	693	9,811
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	2,899	2,694	5,555	1,073	1,505	2,007
ESPP Expense
Advaxis public offerings, net of offering costs			$ 10	$ 11	$ 2
Advaxis public offerings, net of offering costs, shares			10,000,000	10,650,000	2,500,000
Warrant exercises
Warrant exercises, shares		7,500	26,416		15,300
Warrant liability reclassified into equity
Shares issued in settlement of warrants				$ 1	$ 1
Shares issued in settlement of warrants, shares				577,000	856,865
At-the-market shares issued	$ 1
At-the-market shares issued, shares	1,375,337
Commitment fee shares issued for equity line	$ 1
Commitment fee shares issued for equity line, shares	1,084,266
Net Income
Ending balance	$ 62	$ 60	$ 60	$ 20	$ 8	$ 5	$ 62	$ 20
Ending balance, shares	62,714,946	60,252,444	60,236,599	19,248,851	8,020,370	4,646,007	62,714,946	19,248,851
Additional Paid-In Capital [Member]
Beginning balance	$ 433,826	$ 433,614	$ 423,750	$ 407,385	$ 392,335	$ 391,703	$ 423,750	$ 391,703
Stock based compensation	255	210	242	464	479	622
Tax withholdings paid on equity awards	(1)			1	(3)	(11)
Tax shares sold to pay for tax withholdings on equity awards	1			(1)	3	11
Issuance of shares to employees under ESPP Plan	2	2	2	3	7	9
ESPP Expense					1	1
Advaxis public offerings, net of offering costs			9,618	15,478	8,980
Warrant exercises			2		68
Warrant liability reclassified into equity					53
Shares issued in settlement of warrants					5,462
At-the-market shares issued	956
Commitment fee shares issued for equity line	643
Net Income
Ending balance	435,682	433,826	433,614	423,330	407,385	392,335	435,682	423,330
Accumulated Deficit [Member]
Beginning balance	(398,449)	(392,126)	(384,269)	(364,223)	(354,840)	(367,657)	(384,269)	(367,657)
Stock based compensation
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
ESPP Expense
Advaxis public offerings, net of offering costs
Warrant exercises
Warrant liability reclassified into equity
Shares issued in settlement of warrants
At-the-market shares issued
Commitment fee shares issued for equity line
Net Income	(5,829)	(6,323)	(7,857)	(9,858)	(9,383)	12,817
Ending balance	$ (404,278)	$ (398,449)	$ (392,126)	$ (374,081)	$ (364,223)	$ (354,840)	$ (404,278)	$ (374,081)

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jul. 31, 2020	Oct. 31, 2019
Common stock warrant liability, warrants exercisable	$ 33	$ 19
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 33	$ 19

Fair Value - Schedule of Fair_2

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Jul. 31, 2020	May 31, 2020	Oct. 31, 2019	Jul. 31, 2019
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 0.372	$ 0.79	$ 0.372	$ 1.20

Fair Value - Schedule of Change

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2019	Jul. 31, 2020
Beginning balance		$ 19		$ 19
Warrant exercises		2	$ 68
Ending Balance				33
Warrant Liability [Member]
Beginning balance		$ 19		19
Warrant exercises				(2)
Change in fair value				16
Ending Balance				$ 33

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands	Aug. 03, 2020	Jul. 31, 2020
Proceeds from sale of common shares		$ 1,375,337
Subsequent Event [Member] | Lincoln Park Capital Fund, LLC [Member]
Number of common stock shares sold	3,510,527
Gross proceeds from attorney fees and expenses	$ 2,000
Proceeds from sale of common shares	$ 1,900